Semaglutide vs. Tirzepatide: A Complete Head-to-Head Comparison of Efficacy, Side Effects, Dosing, and Outcomes
The two most-discussed drugs in medicine right now are semaglutide and tirzepatide. Together they've transformed obesity treatment, generated hundreds of billions of dollars in revenue, and created a cultural moment around weight loss medication unlike anything before them. Both involve a weekly injection. Both have changed people's lives. Both are expensive and have supply issues and long waiting lists at specialty clinics. But they are not the same drug, and the differences between them matter enormously for individual patients trying to figure out which one to ask their doctor about. This guide cuts through the noise and gives you the actual science, actual trial numbers, and a clear framework for thinking about which one fits which situation.
The Drugs at a Glance
Semaglutide: The Pioneer
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It is available in three branded forms:
- Ozempic (subcutaneous injection, 0.5 mg, 1 mg, 2 mg): FDA-approved for type 2 diabetes management (2017); also reduces major cardiovascular events in T2D patients with established CVD
- Wegovy (subcutaneous injection, 2.4 mg): FDA-approved for chronic weight management in adults with obesity or overweight + comorbidity (2021)
- Rybelsus (oral tablet, 3/7/14 mg daily): FDA-approved for type 2 diabetes (2019); first oral GLP-1 receptor agonist
Semaglutide has been on the market since 2017. It has accumulated years of real-world use, long-term safety data, and remains the most prescribed and most-studied drug in its class.
Tirzepatide: The Disruptor
Tirzepatide is a dual GLP-1/GIP receptor agonist developed by Eli Lilly. It is available in two branded forms:
- Mounjaro (subcutaneous injection, various doses): FDA-approved for type 2 diabetes (2022)
- Zepbound (subcutaneous injection, various doses): FDA-approved for chronic weight management (2023)
Tirzepatide is the newer, higher-efficacy drug — FDA-approved since 2022 for T2D and 2023 for obesity. It consistently outperforms semaglutide in head-to-head clinical comparisons.
Mechanism: Why One Works Better
Semaglutide: GLP-1 Only
Semaglutide is a synthetic analog of GLP-1 (glucagon-like peptide-1) — a naturally occurring gut hormone. It activates only the GLP-1 receptor, producing:
- Glucose-dependent insulin secretion from pancreatic beta cells
- Glucagon suppression from alpha cells
- Delayed gastric emptying (food moves through the stomach more slowly)
- Reduced appetite via CNS signaling through vagal afferents → NTS → hypothalamus
All of these effects operate through the single GLP-1R pathway.
Tirzepatide: GLP-1 + GIP
Tirzepatide activates both GLP-1R and the GIP receptor (GIPR) — two receptors, two overlapping but distinct sets of downstream effects. The GIP component adds:
- Direct insulin-sensitizing effects in adipose tissue via GLUT-4 translocation (fat cells become better at absorbing glucose)
- Additional CNS satiety signaling through hypothalamic GIP receptors
- Synergistic insulin secretion amplification alongside GLP-1 effects
- More potent triglyceride-lowering effects
Beyond the dual targeting, tirzepatide shows biased signaling at GLP-1R — it preferentially activates cAMP over β-arrestin recruitment, which reduces receptor desensitization and internalization compared to semaglutide. The GLP-1R stays active longer, even though tirzepatide binds it with ~5-fold weaker affinity than native GLP-1.
The practical difference: the addition of GIP receptor activation on top of a better-quality GLP-1R signal produces more total weight loss and better glycemic control — not just quantitatively more of the same thing, but qualitatively different metabolic effects.
Efficacy: Clinical Trial Data
Head-to-Head Trial Summary
| Trial | Drug | Dose | Population | Duration | Mean Weight Loss |
|---|
| STEP-1 | Semaglutide | 2.4 mg/week | Obesity, no T2D | 68 weeks | 14.9% |
| SURMOUNT-1 | Tirzepatide | 15 mg/week | Obesity, no T2D | 72 weeks | 20.9% |
| SURMOUNT-5 (head-to-head) | Tirzepatide | Up to 15 mg | Obesity, no T2D | 72 weeks | 20.2% (tirzepatide) vs. 13.7% (semaglutide) |
STEP-1: Semaglutide's Benchmark Trial
STEP-1 was the pivotal obesity trial for semaglutide 2.4 mg (Wegovy). Published by Novo Nordisk and confirmed by the American College of Cardiology:
- 1,961 adults with BMI ≥30 or ≥27 with comorbidities, without T2D
- 68 weeks of treatment
- Mean weight loss: 14.9% (vs. 2.4% placebo)
- 86.4% achieved ≥5% weight loss (vs. 31.5% placebo)
- 32% achieved ≥15% weight loss
When the trial was conducted, these results were described as "unprecedented" — and they were. No previous weight loss drug had come close to 15%.
SURMOUNT-1: Tirzepatide's Flagship Trial
SURMOUNT-1 enrolled 2,539 similar patients and ran 72 weeks, as reported by American Diabetes Association at Scientific Sessions 2022:
- 15 mg dose: 20.9% mean weight reduction (treatment-regimen estimand) / 22.5% (efficacy estimand for completers)
- 91% achieved ≥5% weight loss at 15 mg
- 71% achieved ≥15% weight loss at 15 mg
- 57% achieved ≥20% weight loss at 15 mg
The headline comparison: where semaglutide hit ~15%, tirzepatide hit ~21%. That's a 40% relative improvement in weight loss outcomes at maximum doses.
SURMOUNT-5: The Direct Comparison
SURMOUNT-5 was the first randomized head-to-head trial comparing tirzepatide (up to 15 mg) directly against semaglutide (up to 2.4 mg) — the gold standard for drug comparison. Results as documented in multiple clinical analyses including PeptideDeck 2026:
- Tirzepatide: ~20.2% body weight reduction (~22.9 kg / 50.5 lbs)
- Semaglutide: ~13.7% body weight reduction (~15 kg / 33 lbs)
- Relative difference: tirzepatide produced approximately 47% more weight loss
These were not cherry-picked numbers — this was a randomized controlled trial with both arms simultaneously, designed specifically to answer the "which drug wins?" question. The answer was unambiguous: tirzepatide wins for weight loss.
Real-World Data at 12 Months
JAMA Internal Medicine published a landmark real-world study comparing tirzepatide and semaglutide in clinical practice using electronic health record data from a large US population:
- At 12 months, on-treatment weight change difference favored tirzepatide by 6.9 percentage points (tirzepatide: ~11.4% loss vs. semaglutide: ~6.2% in the full population; larger differences in dose-titrated subgroups)
- Tirzepatide users were:
- 1.8x more likely to achieve ≥5% weight loss
- 2.5x more likely to achieve ≥10% weight loss
- 3.2x more likely to achieve ≥15% weight loss
Rates of moderate-to-severe gastrointestinal adverse events were similar between the two groups.
Weight Loss Milestones Comparison
| Weight Loss Threshold | Semaglutide (STEP-1) | Tirzepatide (SURMOUNT-1, 15 mg) |
|---|
| ≥5% weight loss | 86.4% of patients | 91% of patients |
| ≥10% weight loss | ~70% of patients | 84% of patients |
| ≥15% weight loss | 32% of patients | 71% of patients |
| ≥20% weight loss | 14.8% of patients | 57% of patients |
| ≥25% weight loss | Rare | 36% of patients |
The most striking comparison is at ≥20% weight loss — a goal that represents bariatric surgery-level outcomes: 14.8% of semaglutide patients vs. 57% of tirzepatide patients at maximum dose. This is the clinically most important threshold for patients with severe obesity.
Glycemic Control: HbA1c Reduction in Type 2 Diabetes
For type 2 diabetes patients, both drugs are FDA-approved (Ozempic and Mounjaro respectively) and both reduce HbA1c meaningfully. But tirzepatide consistently shows superior glycemic control:
| Drug | Typical HbA1c Reduction |
|---|
| Semaglutide (Ozempic, 1–2 mg) | ~1.5–2.0% from baseline |
| Tirzepatide (Mounjaro, 10–15 mg) | ~2.0–2.5% from baseline |
The GIP receptor component in tirzepatide provides additional insulin secretion and insulin-sensitizing effects in T2D that GLP-1 alone cannot replicate. For patients with significantly elevated A1c (e.g., >9%), this additional glycemic efficacy is clinically meaningful — the difference between reaching target control (A1c <7%) or not.
Side Effects: The Full Picture
Both drugs belong to the same GLP-1 receptor agonist pharmacological class, so their side effect profiles are similar in kind if not degree.
Side Effect Comparison Table
| Side Effect | Semaglutide 2.4 mg (Wegovy) | Tirzepatide 15 mg (Zepbound) | Notes |
|---|
| Nausea | ~44% | ~42–48% | Most common; peaks during dose escalation |
| Diarrhea | ~30% | ~25–30% | Usually mild; improves with time |
| Vomiting | ~24% | ~20–26% | More common early in titration |
| Constipation | ~24% | ~16–20% | Semaglutide slightly higher |
| Abdominal pain | ~20% | ~15–18% | Both comparable |
| Decreased appetite | Expected (therapeutic) | Expected (therapeutic) | Satiety effect |
| Injection site reactions | Low | Low | Both subcutaneous weekly injections |
| Fatigue | ~11% | ~8–10% | Early treatment; resolves |
| Gallbladder disease/cholelithiasis | ~1.6% | ~0.6% | More common with semaglutide |
| Pancreatitis (rare) | <0.3% | <0.3% | Black box warning both; avoid in MEN2 |
| Thyroid C-cell tumors | Animal risk (class) | Animal risk (class) | Contraindicated with personal/family Hx MTC |
| Lean mass loss | ~25–35% of weight lost | ~25–35% of weight lost | Both; resistance training recommended |
Data from PeptideDeck 2026 clinical analysis and JAMA Internal Medicine real-world comparison.
Is Tirzepatide Really Easier to Tolerate?
Patient communities frequently report that tirzepatide causes less nausea than semaglutide at equivalent efficacy doses. The molecular explanation is biased agonism: tirzepatide recruits less β-arrestin at GLP-1R, which may alter vagal GI signaling differently than full β-arrestin recruitment. The lower constipation rate is also notable.
However, the controlled trial data shows broadly similar GI adverse event rates between the two drugs at their respective maximum doses — the real-world perception of better tolerability may partly reflect comparing well-tolerated doses rather than maximum doses, or may reflect the GIP component's different GI profile partially offsetting the GLP-1 effects.
Dosing Comparison
Semaglutide (Wegovy) Titration Schedule
| Phase | Weekly Dose | Duration |
|---|
| Starting dose | 0.25 mg | 4 weeks |
| Dose 2 | 0.5 mg | 4 weeks |
| Dose 3 | 1.0 mg | 4 weeks |
| Dose 4 | 1.7 mg | 4 weeks |
| Maintenance | 2.4 mg | Ongoing |
Reaches maintenance dose in approximately 16 weeks.
Tirzepatide (Zepbound) Titration Schedule
| Phase | Weekly Dose | Duration |
|---|
| Starting dose | 2.5 mg | 4 weeks |
| Dose 2 | 5 mg | 4 weeks |
| Dose 3 | 7.5 mg | 4 weeks |
| Dose 4 | 10 mg | 4 weeks |
| Dose 5 | 12.5 mg | 4 weeks |
| Maintenance | 15 mg | Ongoing |
Maximum dose reached in approximately 20 weeks. Tirzepatide has more dose steps — useful for fine-tuning tolerability. Important note: the 2.5 mg starting dose is sub-therapeutic; meaningful weight loss begins at 5–7.5 mg.
Cardiovascular Outcomes
Semaglutide: SUSTAIN-6 and SELECT
SUSTAIN-6 (2016): Established semaglutide's cardiovascular safety in T2D patients with high CV risk. Semaglutide significantly reduced MACE (major adverse cardiovascular events) vs. placebo.
SELECT trial (2023): This was the landmark cardiovascular outcomes trial for Wegovy-dose semaglutide. In 17,604 adults with obesity (no T2D) and established cardiovascular disease, semaglutide 2.4 mg weekly reduced the composite of cardiovascular death, non-fatal MI, and stroke by 20% (HR 0.80, p<0.001) compared to placebo — the first drug to receive FDA approval for reduction of cardiovascular risk in patients with obesity who don't have diabetes.
Tirzepatide: SURPASS-CVOT
SURPASS-CVOT (2025): Enrolled 13,165 T2D patients with established ASCVD, comparing tirzepatide to dulaglutide (a GLP-1 agonist). Over ~4 years:
- Tirzepatide was non-inferior to dulaglutide for MACE (HR 0.92; p=0.003 for non-inferiority)
- All-cause mortality 16% lower with tirzepatide (HR 0.84)
- Post-hoc 6-component cardiorenal composite: tirzepatide showed 16% lower incidence (HR 0.84)
Head-to-Head Cardiovascular Comparison
A real-world cohort study published in Nature Medicine emulated both SUSTAIN-6 and SURPASS-CVOT using insurance database data, then directly compared tirzepatide vs. semaglutide:
- In head-to-head comparison: HR 1.06 (95% CI 0.95–1.18) — no significant difference in cardiovascular outcomes between the two drugs in clinical practice
Bottom line on cardiovascular outcomes: Both drugs reduce CV risk significantly versus control. Neither drug has been proven superior to the other for cardiovascular protection in a direct randomized comparison. Semaglutide has more mature long-term cardiovascular data (SELECT trial, approved for CV indication specifically). Tirzepatide's CV data is strong but somewhat newer.
Cost and Insurance Coverage (2025–2026)
List Prices (U.S.)
| Drug | List Price/Month (approximate) | With Manufacturer Coupon |
|---|
| Wegovy (semaglutide 2.4 mg) | ~$1,349/month | ~$0/month (qualifying commercially insured) |
| Zepbound (tirzepatide, up to 15 mg) | ~$1,059/month | ~$0/month (qualifying commercially insured) |
| Ozempic (semaglutide, diabetes) | ~$969/month | ~$0/month (with Novo Nordisk savings offer) |
| Mounjaro (tirzepatide, diabetes) | ~$1,023/month | ~$0/month (with Lilly savings offer) |
Insurance Coverage
The brutal reality: Insurance coverage for obesity medications (Wegovy, Zepbound) — vs. diabetes medications (Ozempic, Mounjaro) — is dramatically different and highly variable by plan.
For diabetes indications (Ozempic, Mounjaro): coverage is generally strong across most commercial and Medicare plans, as these are medically recognized treatment-of-disease medications.
For obesity indications (Wegovy, Zepbound): coverage varies enormously. Many commercial plans do not cover obesity drugs. Medicare Part D historically excluded obesity medications, though policy has shifted somewhat. Government employee plans (some state programs) increasingly cover obesity medications.
Compound GLP-1s: A Warning
During periods of drug shortage (2022–2024), compounding pharmacies legally produced semaglutide and tirzepatide compounds. As brand-name supplies stabilized, the FDA removed both from the drug shortage list, making most compounded versions legally prohibited. As of 2025–2026, obtaining compounded GLP-1s is generally illegal and potentially unsafe — this is an important consumer warning.
Who Does Better on Which Drug: A Decision Framework
Choose Tirzepatide If:
You need maximum weight loss. The data is clear: tirzepatide produces roughly 40–47% more relative weight loss than semaglutide at maximum doses. If you have 50+ lbs to lose and are shooting for ≥20% body weight reduction, tirzepatide's 57% rate of achieving that threshold vs. semaglutide's 14.8% makes the choice obvious.
You have type 2 diabetes with significant insulin resistance. The GIP receptor component improves insulin sensitivity in fat tissue and provides superior HbA1c reduction (2.0–2.5% vs. 1.5–2.0%). For patients with A1c >9% seeking maximum glycemic improvement, tirzepatide's dual mechanism has a clear advantage.
You tried semaglutide and had inadequate results. Patients who did not achieve satisfactory weight loss on semaglutide may respond better to tirzepatide's dual mechanism, which activates additional metabolic pathways.
You have metabolic syndrome. Tirzepatide's GIP component adds significant lipid-lowering (triglycerides particularly) and insulin-sensitizing effects beyond GLP-1 monotherapy, addressing multiple metabolic syndrome components simultaneously.
PCOS with obesity. Real-world data shows ~18.81% weight loss in women with PCOS on tirzepatide, with nearly universal (96.6%) achievement of ≥5% weight loss.
Choose Semaglutide If:
Moderate weight loss goals. If losing 10–15% of body weight would represent success for your situation, semaglutide's proven ~15% efficacy is well-established and sufficient. No need to escalate to a newer, potentially more complex drug.
You prefer oral administration. Rybelsus (oral semaglutide, 7–14 mg daily) is the only approved oral GLP-1 drug. Tirzepatide has no oral formulation as of 2026. For patients with severe needle phobia or adherence concerns with injections, this is a genuine differentiator — though oral semaglutide produces somewhat less weight loss than injectable.
You need the longest safety track record. Semaglutide has been approved since 2017 and has extensive long-term safety data. Tirzepatide (approved 2022) is newer, with a growing but shorter safety database.
Established cardiovascular disease requiring a CV indication. The SELECT trial gave semaglutide a specific FDA indication for reduction of cardiovascular events in obese patients with CVD (without T2D). Tirzepatide does not have this specific labeling yet (though its SURPASS-CVOT data is strong).
Cost and access are primary concerns. Both drugs are expensive, but coverage landscapes favor Ozempic/Mounjaro (diabetes indications) over Wegovy/Zepbound (obesity indications). For T2D patients, both are well-covered; for obesity without T2D, coverage is unpredictable with both.
The "Switching" Question: When and How to Switch Between These Drugs
Switching between semaglutide and tirzepatide is common in clinical practice and generally safe. The most common scenario is switching from semaglutide to tirzepatide in search of greater efficacy.
How to Switch From Semaglutide to Tirzepatide
- No washout required: The drugs work on overlapping pathways; there's no pharmacological need for a drug-free gap.
- Start tirzepatide at 2.5 mg: Standard re-titration from the beginning, regardless of what semaglutide dose was being used.
- Titrate every 4 weeks through the standard schedule to 15 mg maximum.
- Expect initial adjustment: Some patients experience temporary GI effects when switching even if they tolerated semaglutide well — the GIP receptor component is new stimulation.
How to Switch From Tirzepatide to Semaglutide
Less common (usually for cost/coverage reasons or tolerability). The same approach applies: start semaglutide at 0.25 mg and re-titrate through the standard schedule. Do not start at the semaglutide dose that "feels equivalent" to the tirzepatide dose you were on — restart from the beginning.
What to Expect After Switching
Switching from semaglutide to tirzepatide: most patients see additional weight loss once therapeutic tirzepatide doses are established. The Truveta real-world data study showed tirzepatide users were 3.2x more likely to achieve ≥15% weight loss, consistent with enhanced efficacy in switching patients.
What Happens When You Stop Either Drug?
Both semaglutide and tirzepatide are chronic treatments. Weight regain after discontinuation is well-documented:
- STEP-1 extension data showed patients regained approximately two-thirds of their lost weight within 1 year of stopping semaglutide.
- Similar patterns are expected with tirzepatide discontinuation (though specific data is still accumulating).
Both drugs require ongoing use for sustained effect — much like antihypertensives need to be taken continuously for ongoing blood pressure control, or statins need to be taken continuously for ongoing LDL reduction. This is a fundamental aspect of their pharmacology: they are suppressing a biological drive (appetite, caloric intake) that returns when the drug is stopped.
This has significant long-term cost and treatment-planning implications.
Frequently Asked Questions
Q: Is tirzepatide better than semaglutide for weight loss?
A: By all available clinical evidence, yes. In their respective Phase 3 obesity trials (STEP-1 and SURMOUNT-1), semaglutide produced 14.9% mean weight loss at 68 weeks, while tirzepatide at maximum 15 mg dose produced 20.9% at 72 weeks. In the direct head-to-head SURMOUNT-5 trial, tirzepatide produced approximately 47% more relative weight loss (20.2% vs. 13.7%). Tirzepatide's dual GLP-1/GIP receptor mechanism, combined with biased signaling at GLP-1R, produces mechanistically superior metabolic effects.
Q: Are semaglutide and tirzepatide safe long-term?
A: Both drugs have favorable safety profiles based on trial data extending 2–4 years. Semaglutide has a longer real-world track record (approved 2017). Both carry class-level warnings: thyroid C-cell tumor risk (animal data; contraindicated with personal/family history of medullary thyroid cancer or MEN2), pancreatitis risk, and gallbladder disease risk. The most common side effects — GI symptoms — typically improve over time with continued use. No new safety signals have emerged in real-world use for either drug that were not observed in trials.
Q: Can you take tirzepatide and semaglutide together?
A: No. There is no approved or evidence-supported combination regimen. Both drugs activate GLP-1 receptors — adding both together would provide no additional GLP-1 receptor benefit (it's already maximally activated by each drug individually) and would substantially increase GI side effect risk. The appropriate clinical question is not "both drugs" but rather which single drug (or which drug combined with a different class like CagriSema's amylin analog approach) provides optimal benefit for a given patient.
Q: Which drug is better for type 2 diabetes?
A: Tirzepatide shows superior HbA1c reduction (~2.0–2.5%) compared to semaglutide (~1.5–2.0%) across comparable trial populations, driven by the additional GIP receptor-mediated insulin sensitization and secretion effects. For T2D patients with significantly elevated A1c and/or prominent insulin resistance, tirzepatide's dual mechanism offers a meaningful clinical advantage. For patients who are already near-target on glucose control and seeking primarily weight management, the glycemic difference is less clinically decisive.
Q: Which has better cardiovascular benefits — semaglutide or tirzepatide?
A: Both drugs have demonstrated significant cardiovascular benefits. Semaglutide has a specific FDA indication for reducing cardiovascular events in obese patients with CVD (SELECT trial: 20% MACE reduction). Tirzepatide's SURPASS-CVOT showed non-inferiority to dulaglutide and 16% reduction in all-cause mortality. In a real-world head-to-head comparison (Nature Medicine 2025), both drugs showed comparable cardiovascular outcomes (HR 1.06, not statistically different). Currently, semaglutide has the more mature and specifically labeled cardiovascular indication; tirzepatide's data continues to accumulate.
Q: Is there an oral version of tirzepatide?
A: As of 2026, there is no FDA-approved oral form of tirzepatide. Injectable tirzepatide (Mounjaro for T2D, Zepbound for obesity) is the only available formulation. Oral semaglutide (Rybelsus) is available for T2D, and oral Wegovy-equivalent products are in development. For patients who cannot or prefer not to inject, this is a meaningful differentiator favoring semaglutide.
Q: How long does it take to see weight loss results on semaglutide vs. tirzepatide?
A: Both drugs begin working immediately, but meaningful weight loss requires reaching therapeutic doses — which takes 16–20 weeks through titration. Most patients see noticeable results by weeks 8–12. Tirzepatide users tend to see faster and greater cumulative weight loss due to higher peak efficacy, but early-phase results (weeks 4–12) are broadly comparable between the two drugs since both are still in sub-maximum dose ranges. Maximum weight loss is typically achieved at 52–72 weeks of continuous treatment.
Q: What happens to weight after stopping semaglutide or tirzepatide?
A: Weight regain after discontinuation is well-documented and substantial. Extension data from STEP-1 showed patients regained approximately two-thirds of their lost weight within 1 year of stopping semaglutide. The same pattern is expected with tirzepatide. Both drugs work by persistently modulating hunger and metabolic signals — when the drug is removed, these signals revert to baseline, and appetite increases. Most prescribers now consider these medications to be indefinite, maintenance therapies rather than finite courses, similar to how antihypertensives are prescribed.
Q: How much do semaglutide and tirzepatide cost out of pocket?
A: U.S. list prices are approximately $1,349/month for Wegovy and $1,059/month for Zepbound. Manufacturer savings programs can bring costs to near $0 for commercially insured patients who qualify. Insurance coverage for obesity indications (Wegovy, Zepbound) is highly variable — many plans don't cover them. Diabetes indications (Ozempic, Mounjaro) have better coverage. The annual out-of-pocket cost without coverage can exceed $12,000–$16,000, making access a significant equity concern.
Q: Which drug should I ask my doctor about first?
A: For most patients seeking maximum weight loss efficacy with no other complicating factors, tirzepatide (Zepbound) is now generally considered the first-line option by many obesity specialists based on superior trial data. However, if you prefer oral medication, have established CVD where semaglutide's SELECT indication is relevant, have superior insurance coverage for semaglutide, or have a specific cost/access reason, semaglutide (Wegovy) remains a highly effective and medically sound choice. The "right" drug is ultimately the one that is accessible, tolerable, and effective for your specific situation — a decision that requires individual clinical judgment.
Q: Is semaglutide or tirzepatide better for PCOS?
A: Both can benefit PCOS patients through weight loss and insulin resistance improvement. Tirzepatide has stronger real-world evidence in PCOS specifically (18.81% weight loss at 10 months; 96.6% achieving ≥5% loss) and its GIP component's additional insulin-sensitizing effects may be particularly relevant given PCOS's core insulin resistance pathophysiology. However, semaglutide also has documented benefits in PCOS through weight and insulin resistance improvement. Tirzepatide would generally be preferred if the clinical goal is maximum metabolic improvement.
Key Takeaways
- Semaglutide = GLP-1R only; Tirzepatide = GLP-1R + GIPR: The addition of GIP receptor agonism in tirzepatide provides synergistic — not just additive — weight loss and metabolic effects.
- Tirzepatide wins on weight loss: STEP-1 (14.9%) vs. SURMOUNT-1 (20.9%) vs. SURMOUNT-5 head-to-head (~47% more relative weight loss with tirzepatide).
- At the 20% weight loss threshold: 57% of tirzepatide patients vs. 14.8% of semaglutide patients — this is the most clinically important comparison for patients with severe obesity.
- Both drugs are safe long-term, with comparable side effect profiles; tirzepatide may have slightly less constipation, semaglutide slightly higher gallbladder disease rates.
- Cardiovascular outcomes are comparable in real-world head-to-head data, though semaglutide has a specific FDA cardiovascular indication from the SELECT trial.
- Both drugs cause weight regain on discontinuation — these are maintenance therapies for most patients, not finite courses.
- Cost and coverage are significant barriers — both drugs cost ~$1,000/month list price; obesity indications are inconsistently covered by insurance.
- The decision framework: tirzepatide for maximum efficacy, T2D with insulin resistance, obesity with high targets, inadequate semaglutide response; semaglutide for oral preference, established CV disease with SELECT indication, better insurance coverage, moderate weight loss goals.
Citations & References
- Novo Nordisk. "STEP 1 Trial Results." GlobeNewswire. 2020. https://www.globenewswire.com/news-release/2020/06/04/2043954/0/en/Novo-Nordisk-reports-weight-loss-of-14-9-16-9-if-taken-as-intended-in-STEP-1-trial.html
- American College of Cardiology. "STEP 1: Semaglutide Treatment Effect in People With Obesity." 2021. https://www.acc.org/latest-in-cardiology/clinical-trials/2021/02/18/19/23/step-1
- Jastreboff AM et al. "Tirzepatide Once Weekly for the Treatment of Obesity." SURMOUNT-1, NEJM. 2022. https://www.adameetingnews.org/tirzepatide-delivers-substantial-sustained-reductions-in-body-weight-in-surmount-1-obesity-trial/
- Eli Lilly. "SURMOUNT-1 Results." PR Newswire. 2022. https://www.prnewswire.com/news-releases/lillys-surmount-1-results-published-in-the-new-england-journal-of-medicine-show-tirzepatide-achieved-between-16-0-and-22-5-weight-loss-in-adults-with-obesity-or-overweight-301561327.html
- PeptideDeck. "Tirzepatide vs Semaglutide (2026)." 2026. https://www.peptidedeck.com/blog/tirzepatide-vs-semaglutide-comparison-2026
- Kim DJ et al. "Semaglutide vs Tirzepatide for Weight Loss in Adults with Overweight or Obesity." JAMA Internal Medicine. 2024. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080
- Nicholls SJ et al. "SURPASS-CVOT." NEJM. 2025. https://www.acc.org/latest-in-cardiology/journal-scans/2026/01/07/14/20/surpass-cvot
- Cardiovascular outcomes of semaglutide and tirzepatide. Nature Medicine. 2025. https://www.nature.com/articles/s41591-025-04102-x
- Truveta Real-World Data. "Tirzepatide vs Semaglutide 12-Month Study." 2024. https://becarispublishing.com/digital-content/blog-post/truveta-s-real-world-data-study-compares-weight-loss-drugs-tirzepatide-and-semaglutide
- STEP 5 Two-Year Semaglutide Data. Nature Medicine. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9556320/
- SURPASS-CVOT Post-Hoc Cardiorenal Analysis. JAMA Cardiology. 2026. https://pubmed.ncbi.nlm.nih.gov/41903177/
- Medscape. "Tirzepatide Bests Semaglutide in 12-Month Real-World Study." 2026. https://www.medscape.com/viewarticle/tirzepatide-bests-semaglutide-12-month-real-world-study-2026a1000bdg
- Medscape. "Tirzepatide Significantly Lowers Weight in Women With PCOS." 2025. https://www.medscape.com/viewarticle/tirzepatide-significantly-lowers-weight-women-pcos-2025a1000vi8
- Coskun T et al. "Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist." JCI Insight. 2020. https://insight.jci.org/articles/view/140532
